Long-Term Care Deals Hold Steady in Q2:17

Merger and acquisition activity stayed virtually even in the second quarter, down 1% from the previous quarter, to 75 transactions. The quarter’s deal volume makes up 24% of the 315 deals announced within the past 12 months. Q2:17’s deal volume is 17% lower than the same period a year earlier.

Home Health and Hospice Sector Hit by Headwinds

The Home Health & Hospice sector has experienced a few headwinds in 2017. Besides the ongoing labor shortage, reimbursement levels would be severely impacted by the passage of the Senate Republicans’ Better Care Reconciliation Act, which curtails federal spending on Medicaid beginning in 2020.

Behavioral Health Deals Tumble in Q2:17

Deal activity in the Behavioral Health Care sector plummeted in Q2:17, down 50% compared with the previous quarter, and down 53% compared with the same quarter a year earlier. The quarter’s total of eight deals represents 21% of the 39 transactions announced in the past 12 months. In fact, those two  quarters—Q1:17 and Q2:16—had the […]

Alere Spins Off Assets to Aid Abbott Merger

Since February 2016, we’ve followed the testy merger between Abbott (NYSE: ABT) and Alere’s (NYSE: ALR) agreement to merge, followed by the respective lawsuits, and then the price renegotiation. Half way through 2017, the $5.3 billion deal is getting closer to completion, as Alere spins off some assets to comply with antitrust regulations.

Sanofi Rationalizes Its Vaccine Portfolio

Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including […]